68 results about "Photoreceptor cell" patented technology

A brain organoid containing optic vesicles generated based on H9 induction and an eye-brain fusion culture method thereof are provided. H9 embryonic stem cell induction is used to generate a brain organoid containing optic vesicles with primitive visual field. Based on an established optic vesicle brain organoid culture system, microscopic imaging is combined with specific marker antibodies related to early retinal development and photoreceptor cell maturation to structurally and functionally identify the brain organoid containing optic vesicles.

The invention belongs to the technical field of medicines, and particularly relates to application of Comput-8 in preparation of a product for relieving or treating retina degeneration induced by blue light damage. It is found for the first time that Compond-8 has a protection effect on retina rod cells and cone cells induced by blue light damage, the cilia length, density and membrane disc thickness of the cone cells and the rod cells can be increased, the thickness of a retina outer nuclear layer can be increased, photoreceptor cell damage caused by blue light exposure can be remarkably improved, and the photoreceptor cell damage can be remarkably reduced. The retina degeneration caused by blue light injury can be relieved or treated, and a new thought and means are provided for treatment of the retina degeneration induced by the blue light injury.

The present disclosure provides short enhanced human opsin promoters for rod-specific expression that satisfy a need in the art for promoters that are able to control transgene expression both efficiently and selectively in rod cells, with little to no off-target expression in other photoreceptor cells. The disclosure provides vector constructs comprising transgenes operably controlled by this enhanced human opsin promoter that may be delivered and targeted with high specificity to rod cells. The disclosure also provides compositions comprising these vector constructs and methods for administration of these compositions to subjects in need thereof.

Injectable photoelectrohydrogel for repairing retinal photoreceptor damage and its preparation method and application, photoelectroactive spirulina and conductive polymer poly(3,4-ethylenedioxythiophene) (PEDOT) hydrogel are physically cross-linked to construct an injectable material with photoelectric response characteristics, and the function of damaged photoreceptor cells in the retina is repaired in situ. Sp as a biologically active component not only gives the material photoelectric signal conversion capability, but also can achieve local antioxidant stress function, PEDOT-based hydrogel forms a three-dimensional scaffold by physically wrapping Sp, which not only ensures the activity of algal cells but also has excellent charge and ion conduction performance. The hydrogel can be injected into the retina to construct a biomimetic electrochemical signal transmission interface, rebuild the signal transduction of damaged photoreceptor cells, and realize the in situ repair of retinal signal pathways and the partial recovery of visual function. This technology provides a new strategy for the curative treatment of retinal diseases such as blinding eye diseases, and has the advantages of minimally invasive intervention, excellent biocompatibility and customizable treatment area.

The invention relates to the technical field of biological medicine, in particular to application of aronia melanocarpa extract in prevention and / or treatment of retinal diseases. The invention discovers that the aronia melanocarpa extract effectively protects the functions of photoreceptor cells and bipolar cells by remarkably improving the expression of rhodopsin (RGO) and stem inhibition protein (SAG) genes in the retina and inhibiting the up-regulation of inflammatory factors TNF-alpha at the same time; in addition, cell apoptosis caused by light damage can be relieved by reducing TUNEL positive cells of the retinal outer nuclear layer (ONL), and therefore the structural integrity of the retina is maintained on the cellular level. Through the mechanisms, the aronia melanocarpa extract recovers normal electrophysiological reactions of photoreceptors and bipolar cells and protects the retina from further injury. The invention provides an effective strategy and theoretical basis for application of the aronia melanocarpa extract in prevention and treatment of retinal diseases caused by light damage.

The disclosure relates to methods of treating photoreceptor disease and / or inhibiting degeneration or death of photoreceptors. The methods comprise administering to a subject in need thereof a therapeutically effective amount of an inhibitor of mitogen-activated protein kinase 11 (MAPK11), an inhibitor of casein kinase 1 (CK1), or combinations thereof. This disclosure also relates to certain inhibitors of MAPK11 or CK1 and to pharmaceutical compositions that contain such inhibitors.

The utility model relates to a kind of delay myopia degree progress and axial growth prevention and control spectacle lens, belong to the field of glasses optics.The lens includes lens base, and the center area is circular center visible area, and outside is peripheral defocus area.Peripheral defocus area is composed of microlens array, and is divided into two asymmetric design regions from central axis: upper half adopts circular ring array structure, and lower half adopts concentric honeycomb array structure.Effective inhibition vision deepens, improve myopia management effect.Peripheral defocus area defocus gradually reduces from center to outside, more fit 8-18 years old teenager eyeball retina structure features.Microlens gap place evenly densely multiple diffusion points, effectively reduce contrast, brightness by soft scattered light, reduce hue difference;Reduce the high contrast signal detected by retina photoreceptor cell and its elongation signal to eye, so as to delay axial growth, delay myopia deepens.

This invention discloses the application of the VDAC2 gene or VDAC2 protein as a target in screening drugs for the treatment of retinitis pigmentosa, relating to the field of biomedical technology. The drug is one that reduces the expression level of the VDAC2 gene or inhibits the expression level or activity of the VDAC2 protein; the CDS sequence of the VDAC2 gene is shown in SEQ ID NO.1. This invention uses a rod cell-specific promoter to inhibit VDAC2 expression, which can significantly improve the survival rate of local photoreceptor cells. This method intervenes in the early stages of the disease, conforming to the natural course of RP. It strengthens the function of rod cells before a large number of photoreceptor cells die, delaying their degenerative process and indirectly protecting cone cells, thereby prolonging the patient's effective visual retention time. This overcomes the shortcomings of existing gene therapies, which are mainly applicable to late-stage or specific mutation types, and provides a therapeutic basis for retinitis pigmentosa.

The present disclosure relates to compositions, methods and related uses for preventing, inhibiting, ameliorating or delaying (slowing): (i) the thinning of the retinal outer nuclear layer (ONL), and / or (ii) reduction in total retinal thickness in a subject. The present disclosure further relates generally to compositions, methods and related uses for protecting: (i) the retinal outer nuclear layer (ONL) and / or the retina from light- or age-induced damage, and / or (ii) photoreceptors from light- or age-induced damage. In particular, the present technology relates to administering bevemipretide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof to subjects in need thereof.

The invention belongs to the technical field of biology, and relates to a construction method of a renal tubular interstitial nephritis-uveitis syndrome mouse model. Comprising the following steps: anesthetizing a mouse; carrying out subcutaneous injection on photoreceptor intercellular vitamin A binding proteins and a complete Freund's adjuvant on the front neck, the thighs on the two sides and the back of the anesthetized mouse, and carrying out active immunization; and performing intraperitoneal injection on the actively immunized mouse by adopting pertussis toxin, and performing final immunization. According to the invention, the renal tubular interstitial nephritis-uveitis syndrome mouse model is successfully constructed, so that a foundation is laid for subsequent pathological mechanism research of the disease, and a support can be provided for further development of medicine research for treating the disease.

This approach provides an opportunity to inhibit photoreceptor degeneration by knocking out the SARM1 gene, thereby sustaining photoreceptors in the eye. [Solution] A method is provided for inactivating alleles of the steryl alpha and toll / interleukin-1 receptor motif-containing 1 (SARM1) gene in cells, comprising introducing into the cells a composition comprising at least one CRISPR nuclease, or a sequence encoding a CRISPR nuclease; and an RNA molecule comprising a guide sequence portion, wherein the complex of the CRISPR nuclease and the RNA molecule acts to break the double strand in the allele of the SARM1 gene, and the guide sequence portion of the RNA molecule comprises 17 to 50 consecutive nucleotides.

The invention discloses application of Hinderein protein in regulation and control of cilia length and the fields of biomedicine and molecular cell biology, in-vivo and in-vitro experiments prove that knockdown or knockout of Hinderein can cause significant shortening of cilia length of mouse retina photoreceptor cells and APRE19 cells, but does not affect the occurrence rate of cilia, and mechanism research shows that knockdown or knockout of Hinderein can cause significant shortening of cilia length of mouse retina photoreceptor cells and APRE19 cells without affecting the occurrence rate of cilia. The Hinderein interacts with the central grain satellite protein PCM1, and is crucial to the positioning of the Hinderein around the central grain. Therefore, the Hinderein protein, the agonist of the Hinderein protein or the coding gene of the Hinderein protein can be used for preparing products for promoting cilia elongation, and a new target spot is provided for treatment of diseases related to abnormal cilia length.

This suppresses image defects caused by toner being reverse-transferred to the photoreceptor. [Solution] The image forming apparatus comprises a photoreceptor, a charging member, a developing unit, a transfer unit, a recovery member disposed downstream of the transfer unit and upstream of the charging member, which electrostatically recovers the reverse transfer toner having a first color transferred from the transfer member to the surface of the photoreceptor by the transfer unit, and a control unit that controls the voltage applied to the charging member and the recovery member, respectively. When the absolute value of the potential of the recovery member during image formation is V1 and the absolute value of the surface potential of the photoreceptor before passing through the recovery member is V2, the control unit controls V2

A method of treating a cone photoreceptor cell-associated disorder in a subject in need of such therapy by administering to the eye of the subject a recombinant vector comprising: (a) a coding sequence encoding a synoviolin 1 (SYVN1) protein, and (b) a promoter region, wherein the promoter region is specific for cone photoreceptor cells, wherein the coding sequence is operatively linked to the promoter region, and wherein in vivo expression of the SYVN1 protein in the cone photoreceptor cells of the subject serves to treat the cone photoreceptor cell-associated disorder in the subject.

Methods are provided for treating and diagnosing diseases and disorders associated with retinal degeneration, such as retinitis pigmentosa. Dietary supplementation with specific metabolites and vitamins can prolong vision and provide a neuroprotective effect. In particular, dietary supplementation with a-ketoglutarate, or a derivative thereof, significantly prolongs photoreceptor cell survival and visual function. In addition, dietary supplementation with B vitamins and a ketogenic diet also improves photoreceptor cell survival and delays disease progression in some cases. Additionally, compositions, methods, and kits are provided for diagnosing a subject with retinitis pigmentosa based on expression levels of vitreous biomarkers.

As a technique useful in genome editing of a rhodopsin (RHO) locus using a zinc finger nuclease (ZFN), a combination of one pair of ZFNs, which is a combination of ZFNs having a zinc finger array that recognizes a specific nucleic acid sequence, for genome editing of the RHO locus is provided.

The present invention relates to retinal progenitor cells simultaneously exhibiting characteristics of retinal pigment epithelial cells, photoreceptor cells, and lens epithelial cells, and a mass production method therefor. When retinal progenitor cells are isolated and cultured using the method according to one aspect, the retinal progenitor cells can be mass-produced in a short time, and thus the method is economical. In addition, the isolated retinal progenitor cells exhibit all of the differentiation characteristics of retinal pigment epithelial cells, photoreceptor cells and lens epithelial cells. Therefore, the present invention can be effectively used in the fields of research on retinal diseases such as macular degeneration, and research and development of therapeutic agents.

Provided are a photoreceptor cell-specific bidirectional promoter and the use thereof. Specifically, the present invention relates to a new photoreceptor cell-specific bidirectional promoter, an expression cassette, vector, virus particle, cell and pharmaceutical composition containing the bidirectional promoter, and the use thereof in the treatment of ocular diseases such as retinal diseases.

A brain organoid containing optic vesicles generated on the basis of H9 induction and an eye-brain integrated culture method therefor. H9 embryonic stem cells are used to induce the generation of a brain organoid which contains optic vesicles and has primitive visual fields. On the basis of an established system for culturing a brain organoid containing optic vesicles, and by means of microscopic imaging in combination with antibodies against specific markers related to early retinal development and photosensitive cell development and maturation, the structure and function of the brain organoid containing optic vesicles are identified.

The present disclosure relates to compositions, methods and related uses for preventing, inhibiting, ameliorating or delaying (slowing): (i) the thinning of the retinal outer nuclear layer (ONL), and / or (ii) reduction in total retinal thickness in a subject. The present disclosure further relates generally to compositions, methods and related uses for protecting: (i) the retinal outer nuclear layer (ONL) and / or the retina from light- or age-induced damage, and / or (ii) photoreceptors from light- or age-induced damage. In particular, the present technology relates to administering bevemipretide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof to subjects in need thereof.

This invention discloses the application of disodium 4,4'-diisothiocyanate-2,2'-stilbene sulfonate in the preparation of drugs for the prevention, delay, and / or treatment of blue light-induced retinal damage. It belongs to the field of biomedical technology. This invention demonstrates for the first time that sodium DIDS can effectively protect photoreceptor cells from blue light damage: at the cellular level, sodium DIDS can restore mitochondrial membrane potential, increase ATP levels, reduce reactive oxygen species accumulation, and inhibit mitochondrial-dependent apoptosis; at the animal level, intravitreal injection of sodium DIDS can improve vision in mice exposed to blue light, restore the amplitude of a-waves and / or b-waves in electroretinograms, and protect the outer segment length and outer nuclear layer thickness of cone cells. Sodium DIDS provides a novel therapeutic strategy for blue light-induced retinal photodamage through multi-target synergistic protection of mitochondrial function.

A blade (1) for a wind power generator has a surface covered with a reflective material layer (12) made of a light-reflecting material that reflects light such that, when light is incident on a compound eye of an insect, at least three types of photoreceptor cells present in the ommatidium constituting the compound eye contain visual pigments having different absorption wavelength bands, which are the wavelength bands of light to be absorbed, and the difference in light intensity in the absorption wavelength bands of the visual pigments contained respectively in multiple types of photoreceptor cells constituting a part of the ommatidium of the compound eye of the insect that are excited upon absorption of light is equal to or less than a predetermined intensity difference threshold.

The invention discloses application of salvianolic acid C in preparation of a medicine for preventing and / or treating retinal ischemia hypoxic nerve injury diseases, and relates to the technical field of biological medicines. The invention proposes and verifies for the first time that salvianolic acid C can significantly promote the formation of stress particles in photoreceptor cells under retinal ischemia and hypoxia conditions, and drives the salvianolic acid C to be assembled into a stress particle-mitochondrial micro-region in a mitochondrial adjacent region. The microcell is enriched in DDX3X, LARP1 and other key RNA binding proteins and multiple mitochondrial related proteins to cooperatively maintain mitochondrial membrane potential, inhibit mPTP opening and reduce ROS generation, so that an endogenous apoptosis pathway is inhibited, and the neuroprotective effect on a photoreceptor is achieved. On the basis, the salvianolic acid C is used for preparing the medicine for preventing and / or treating the retinal ischemia hypoxia nerve injury disease, can be used as a nerve protection supplement for existing anti-VEGF treatment, and has innovativeness and application value.

The present technology provides methods for treating (wet or dry) age-related macular degeneration (AMD). In particular, the present technology relates to the use of elamipretide, or a pharmaceutically acceptable salt thereof, in effective amounts to treat (wet or dry) age-related macular degeneration (AMD) and thereby decrease the rate of growth of photoreceptor loss over time in a subject, such as a mammal (e.g., a human).

Provided herein are genetically engineered promoter-enhancer constructs for altering transcription of a gene operably linked thereto having specificity for expression in photoreceptor cells. Also provided are methods of use for these photoreceptor-specific promoter-enhancer genetic constructs; a pharmaceutical composition comprising these constructs, and methods of using the pharmaceutical composition for treating retinal diseases.

The blade (1) for a wind power generator has a surface covered with a reflective material layer (12) made of a light-reflecting material that reflects light such that when light is incident on an insect's compound eye, at least three types of photoreceptors present in the ommatidium that make up the compound eye contain visual pigments with different absorption wavelength bands, which are the wavelength bands of light that the photoreceptors absorb, and the difference in light intensity in the absorption wavelength bands of the visual pigments contained in each of the multiple types of photoreceptors that make up part of the ommatidium of the insect's compound eye become excited when they absorb light, is equal to or less than a predetermined intensity difference threshold.

Provided are compositions containing microalgae extracellular vesicles (MEVs) formulated for administration to the eye for treatment of diseases, disorders, and conditions of the eye, particularly for diseases, disorders, and conditions that involve tissues and cells in the back of the eye, which generally cannot be treated with eyedrops. Upon administration to the eye, the MEVs deliver therapeutics to tissues that include the choroid, retinal pigment epithelium cells, and photoreceptor cells. The compositions contain extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo for treating or diagnosing or monitoring a disease, disorder, or condition of the eye or involving the eye. Methods of treatment of diseases, disorders, and conditions of the eye are provided.

The application discloses application of TAPI-1 in preparation of a drug for treating dry age-related macular degeneration, and belongs to the technical field of biological medicine. A dry age-related macular degeneration mouse model is constructed by using sodium iodate, and a TAPI-1 solution is injected into the vitreous body for treatment, and structural examination and histopathological examination are conducted on the mouse. The experimental results show that, compared with the control group, the retinal choroid structure of the mouse treated by TAPI-1 is more complete, the fundus lesion area is less, the damage degree of the pigment epithelium and the photoreceptor cell is lighter, and the expression level of the inflammatory molecules in the ocular tissue is lower, and the treatment effect is significant. The application firstly proposes that TAPI-1 is used for preparing a drug for treating and / or preventing dry age-related macular degeneration, a new treatment strategy is provided for the dry age-related macular degeneration, and the application has a wide application prospect.

The transdifferentiation of glial cells into neurons is useful for prevention or treatment of a disease associated with loss of function or death. The present disclosure relates to the field of biomedicines. More specifically, the present disclosure relates to use of a REST inhibitor in the treatment of a disease associated with loss of function or death of neurons. The present disclosure can effectively induce transdifferentiation of astrocytes into dopamine neurons by inhibiting the expression, content or activity of a gene of REST or an RNA thereof or an encoding protein thereof in astrocytes in the brain, and can effectively induce transdifferentiation of Müller glia (MG) into retinal ganglion cells (RGCs) or photoreceptor cells by inhibiting the expression, content or activity of the gene of REST or the RNA thereof or the encoding protein thereof in the retina, thereby preventing and / or treating the disease associated with loss of function or death of neurons.

The present invention provides a method of making a cone degeneration model comprising the step of activating specific cell death in at least one cone photoreceptor cell. Also provided are methods for isolating compounds capable of protecting cone photoreceptor cells from denaturation.